Navy Federal and the National Flag Foundation Team Up on Light to Unite Initiative for America’s 250th Anniversary
VIENNA, Va.–(BUSINESS WIRE)–#America250–To celebrate America’s 250th Anniversary, Navy Federal Credit Union is proudly the national presenting... Read more.
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates... Read more.
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$NNOX—The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit... Read more.
MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$MSFT—The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit... Read more.
Gay Qatari Refugee Returns to Face Qatar at the World Cup, Standing With Senator Scott Wiener to Say Love Is Not a Crime
Dr. Nasser Mohamed, the first openly gay Qatari to seek asylum, appears at San Francisco’s Qatar match alongside Senator Scott Wiener to declare that love is not... Read more.
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed... Read more.
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses,... Read more.
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #Bosulif–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along... Read more.
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
– frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade... Read more.
ComEd Continues Power Restoration Following Two Powerful Storms
Crews focus on remaining outages as weather clears across northern Illinois CHICAGO–(BUSINESS WIRE)–ComEd crews continue restoring power to customers... Read more.